In conclusion, our study demonstrates that MVA-B is a broadly immunogenic HIV/AIDS vaccine candidate that stimulated polyfunctional HIV-specific CD4 T cell responses with a T effector memory (TEM) phenotype in HIV-1-infected patients on HAART, and also enhances vector-specific CD8 T cell responses. This evidence concerns the gene CD4 and AIDS.